In addition, even in PTEN-deficient cancer cells, a selective inhibitor of PI3Kβ only led to transient suppression of, followed by a significant rebound in phospho-AKT levels, which were attributed to the upregulation of the IGFR1–IRS1–p110a signaling cascade. This evidence concerns the gene PTEN and cancer.